Mutations to the SARS-CoV-2 viral genome, resulting in the rise of new variants, have been associated with increased risk of hospitalization, ICU admission, morbidity, and mortality 62,63. The Beta and Delta variants posed a greater risk in terms of the above mentioned factors when compared to the less virulent Alpha and Gamma variants 63. Interestingly, estimates of the severity of the newest Omicron VOCs propose a lower risk of serious infection (per person infected) requiring hospitalization when compared to the previous dominant variant, Delta 64,65. The impact of SARS-CoV-2 genome mutations on COVID-19 associated coagulopathy is not well documented. In this study, we compared WB TEG® blood clotting parameters, and prevalence of microclots of healthy individuals to COVID-19 participants that have been infected by different SARS-CoV-2 variants.
A spectrum of hypercoagulability is predicted to present among different COVID-19 variants. The early Alpha variants, and successive Beta and Delta variants, caused more hypercoagulability as documented by the incidence of venous thromboembolism, and reflected by hypercoagulopathic parameters of TEG®s including fibrinolytic shutdown 28,66 than what is presumed to be seen in subsequent Omicron variants. In our patient population, the majority of the β/Δ variants were sicker and included recruitment from the inpatient population, whereas all the Omicron variants were less ill and were recruited only from the outpatient population. Using the WHO Clinical Progression Scale, we determined that our Omicron population experienced significantly less severe disease states compared to our β/Δ population. This study did not calculate APACHE II & IV, or SOFA scores for the COVID-19 positive population, yet it is clear that these scores were much lower for the non-hospitalized Omicron patients. Thus, there has been significant literature published regarding the validity of these prediction tools as well as precision-based proteomics algorithms which rely on machine-learning 55,67− 70. In this study, we demonstrated TEG® results and their ability to distinguish differing degrees of hypercoagulability among the variants. A large proportion of critically ill COVID-19 patients will present with hypercoagulable TEG® profiles 45,71,72. Omicron patients are met with reduced odds of developing severe disease 73, leading to the assumption of less hypercoagulable TEG® profiles. The results presented here do indeed indicate lesser hypercoagulability in our Omicron population when compared to healthy individuals versus our β/Δ population when compared to the same set of healthy individuals. A direct comparison between the Omicron population and β/Δ population indicated a significantly higher maximum amplitude in the β/Δ population.
Fibrinolytic abnormalities can occur in COVID-19 with fibrin deposits previously seen in the lungs 74 and hearts 75 of positive patients. The present study found a significant amount of fibrin amyloid microclots in the PPP of β/Δ samples and to a lesser extent Omicron samples. Microclots have previously been proven to be highly resistant to fibrinolysis and it was also shown that inflammatory molecules and plasmin inhibitors can become entrapped in them 32. Similar to this, Wygrecka et. al. found that abnormal fibrin structure and dysregulated fibrinolysis collectively contribute to a high incidence of thrombotic events in COVID-19 76. Abnormal fibrinogen levels are a prominent factor associated with COVID-19 induced coagulopathy 77− 79. This study did not measure fibrinogen levels; however, previous studies show that elevated fibrinogen correlates with excessive inflammation, disease severity and ICU admission in COVID-19 patients 80. Our results show statically significant tapering in amount of microclots from β/Δ to Omicron to healthy individuals. The TEG® parameters did indicate a spectrum of hypercoagulability among the different COVID-19 variants, however to a lesser extent than the microclot results since direct comparison of the Omicron population to β/Δ population indicated significance.
We suggest that TEG/ROTEM and plasma microclot analysis, as personalized point-of-care medicine tools, may fill the gaps in these evidence-based recommendations for safely and effectively titrating thromboprophylaxis or anticoagulation. Although we did not directly show a lower risk of clinically significant macro-thrombosis for Omicron variants, this study is the first of its kind to directly study differing degrees of hypercoagulability among the less virulent Omicron and more virulent β/Δ variants. The severity of COVID-19 associated coagulopathy is largely due to severity of illness and correlates well with disposition; thrombotic and hemorrhagic events correlate positively to intensive-level care 81. Since Omicron less frequently causes severe illness and hospitalization, it was thought also to confer lesser hypercoagulability along the spectrum of COVID-associated coagulopathy. This study supports that hypothesis. Beyond the hospitalized COVID-19 patient, these results also have implications for the surgical patient undergoing elective surgery while afflicted with acute or convalescent COVID-19 82. The surgeon may use TEG/ROTEM and plasma microclot analysis to contextualize the patient’s coagulopathy and thrombohemorrhagic risk in the perioperative period. TEG/ROTEM has established operative use in cardiac surgery, liver transplantation, and trauma resuscitation 83,84. We propose that acute or convalescent COVID-19 should be a relative indication for adjunctive TEG/ROTEM use for the perioperative patient undergoing an emergent or elective procedure.
In the present study we did not focus on platelet activity. The role of platelets in COVID-19 associated coagulopathy is complex. Platelet hyperactivation fuels the thrombo-inflammatory milieu associated with disease severity in moderate to severe COVD-19 85–89. Similarly, SARS-CoV-2 can directly bind to platelet angiotensin-converting enzyme 2 (ACE2) via its spike glycoprotein to enhance thrombotic activity 90. Thrombocytopenia is another important platelet associated complication of COVID-19 91–93. The pathophysiology of thrombocytopenia in COVID-19 is not fully understood, but has been proposed to involve several mechanisms 94. As the mechanism may differ, the strategies to remedy this thrombocytopenia might be different, rendering the need for serious caution when approaching treatment 95. Traditional platelet functional assays are reliable, but show very limited potential in clarifying platelet phenotypic heterogeneity and interactions 96. Considering this in combination with the lack of pre-existing knowledge distinguishing the impact of differing SARS-CoV-2 variants on coagulation, and the multifaceted role platelets may play in COVID-19, highlights the need for alertness when approaching research in this uncharted territory. Advancements in techniques such as flow cytometry, electron microscopy, mass spectrometry, and ‘omics’ have started to open up new avenues in platelet research 96, paving the way for follow up studies to expand and add to the personalized-based medicine tools presented here.